Clinical trial
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors
NCT00389389 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00389389 |
|---|---|
| Title | Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors |
| Official title | A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly or Every Two Weeks in Patients With Advanced Solid Malignancies |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | AZD4877 |
| Enrollment | 75 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Oct 18, 2006 |
| Last update posted | May 1, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: